← Russell 3000 cross-section

RIGL RIGEL PHARMACEUTICALS INC

Trailing twelve months to 2026-06-30 · as filed 2026-08-04, not restated
Healthcare

Scale

Market cap
$866m
Revenue TTM
$277m
Net income TTM
$322m
Free cash flow
Composite score
72.6
Sector rank
#2105

Valuation

P / E
2.7
EV / EBITDA
8.6
EV / sales
2.8
FCF yield
Earnings yield vs 10-yr
32.45pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
116.3%
EBITDA margin
32.4%
ROE
75.7%
ROIC
26.4%
Revenue growth
3.3%

Insider activity, last 90 days

Net open-market
$-0.09m
Buyers
0
Sellers
1

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Business Updates Commercialized Products TAVALISSE net product sales for the six months ended June 30, 2026 were $84.7 million, an increase of $16.1 million, or 24%, compared to $68.5 million for the same period in 2025. The increase was primarily driven by higher volumes and higher price per bottle, as well as a favorable impact from lower revenue reserves. REZLIDHIA net product sales for the six months ended June 30, 2026 were $17.0 million , an increase of $3.8 million, or 29%, compared to $13.1 million for the same period in 2025 . The increase was primarily driven by higher volumes and higher price per bottle, partially offset by higher revenue reserves. …RIGEL PHARMACEUTICALS INC, 10-Q, period ended 2026-06-30, filed 2026-08-04

Read the full passage →